Hybrid Ordered Mesoporous Materials as Supports for Permanent Enzyme Immobilization Through Non‐covalent Interactions

Gascón, Victoria; Márquez‐Álvarez, Carlos; Dı́az, Isabel; Blanco, Rosa M.

doi:10.1002/9781119113874.ch19

Cited by 10 publications

(6 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding post‐synthesis immobilization via noncovalent attachment, in order to promote interaction between the enzyme and the support, three amino‐functionalized silica materials (MS‐3030‐g‐N, LP‐SBA‐15‐co‐N and LP‐FDU‐12‐g‐N) were considered. The immobilization on these amino‐functionalized silica supports was performed at pH 5.5 at which the surface of the support is positively charged due to protonation of amino groups . At this pH, higher than the isoelectric point of the enzyme (pI = 4.0), the enzyme surface would be negatively charged, so electrostatic interactions control the adsorption process (Scheme S5).…”

Section: Resultssupporting

confidence: 69%

“…The immobilization on these amino-functionalized silica supports was performed at pH 5.5 at which the surface of the support is positively charged due to protonation of amino groups. 35 At this pH, higher than the isoelectric point of the enzyme (pI = 4.0), the enzyme surface would be negatively charged, so electrostatic interactions control the adsorption process (Scheme S5). Post-synthesis immobilization of -Glu via electrostatic interactions also yielded low enzyme loadings (Table S3), reaching a maximum value of 7.6 mg g −1 for LP-SBA-15-co-N.…”

Section: Post-synthesis Immobilization Of -Glumentioning

confidence: 99%

See 1 more Smart Citation

Successful encapsulation of β‐glucosidase during the synthesis of siliceous mesostructured materials

Gascón

Márquez‐Álvarez

Blanco

2018

J of Chemical Tech & Biotech

Self Cite

View full text Add to dashboard Cite

BACKGROUND The biocatalysis field demands ‘universal’ supports able to encapsulate enzymes with a straightforward methodology, and at the same time, capable of retaining their catalytic activity. The employment of siliceous materials for such a purpose is a big challenge because drastic synthesis conditions are required and improved functionalization is needed to increase affinities towards the targeted enzyme. In this work, a compromise between the development of a well‐formed mesostructured support and an acceptable enzymatic activity was attempted via the in‐situ immobilization approach. RESULTS The immobilization of β‐glucosidase (EC 3.2.1.21) from Aspergillus niger was approached using different strategies. After trying to immobilize β‐glucosidase with a post‐synthesis approach, nonhigh loadings were achieved both with covalent linkage (using epoxy activated supports; 3.5 mgE g−1) and with noncovalent bonding (using amine‐functionalized materials; 7.6 mgE g−1). However, when the in‐situ approach was attempted, success in reaching the highest enzyme loading (close to 200 mgE g−1) was achieved. CONCLUSION In this work, the support cages around the in‐situ encapsulated enzyme fully prevented its release through the narrow windows connecting cages, achieving a less than 5% release of the initially desorbed protein, as well as a further total absence of leaching. This enabled the biocatalyst to be reused at least eight times more without any loss in activity. © 2018 Society of Chemical Industry

show abstract

Section: Resultssupporting

confidence: 69%

Section: Post-synthesis Immobilization Of -Glumentioning

confidence: 99%

Successful encapsulation of β‐glucosidase during the synthesis of siliceous mesostructured materials

Gascón

Márquez‐Álvarez

Blanco

2018

J of Chemical Tech & Biotech

Self Cite

View full text Add to dashboard Cite

show abstract

“…Non-covalent approaches by using adapter biomolecules avoid randomly oriented antibodies [ 119 ]. The most relevant binding strategy exploits the biotin–avidin interaction, which is based on the strong binding affinity between biotin and a biotin-binding protein, such as avidin or its analogues [ 120 , 121 ] (See Figure 1 B).…”

Section: Conjugation Strategies For Acnp Generationmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

show abstract

“…Non-covalent approaches using adapter biomolecules can provide orientation of the immobilized antibodies on the NP surface [ 58 ]. The most relevant binding strategy with adapter molecules exploits biotin–avidin interaction as the strongest non-covalent biological interaction between a protein and a ligand [ 59 ]. The most common approach using biotin–avidin interaction implies chemical modification of the antibody with biotin (biotinylation) and functionalization of the nanoparticle with avidin or its derivatives [ 60 ].…”

Section: Selective Targeting Of Breast Tumorsmentioning

confidence: 99%

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Juan

Cimas

Bravo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

show abstract

Hybrid Ordered Mesoporous Materials as Supports for Permanent Enzyme Immobilization Through Non‐covalent Interactions

Cited by 10 publications

References 88 publications

Successful encapsulation of β‐glucosidase during the synthesis of siliceous mesostructured materials

Successful encapsulation of β‐glucosidase during the synthesis of siliceous mesostructured materials

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Contact Info

Product

Resources

About